(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.
Imunon's earnings in 2026 is -$14,329,403.On average, 5 Wall Street analysts forecast IMNN's earnings for 2026 to be -$11,659,055, with the lowest IMNN earnings forecast at -$14,128,848, and the highest IMNN earnings forecast at -$8,865,647. On average, 5 Wall Street analysts forecast IMNN's earnings for 2027 to be -$11,315,176, with the lowest IMNN earnings forecast at -$14,521,546, and the highest IMNN earnings forecast at -$7,737,292.
In 2028, IMNN is forecast to generate -$8,690,637 in earnings, with the lowest earnings forecast at -$9,026,841 and the highest earnings forecast at -$8,220,873.